Vanda’s success comes from our ability to remain consistent. That is, maintaining the same high standards throughout the entire product development process, and never losing sight of our ultimate goal–improving patients’ lives.
Data as of 07/30/21
Minimum 20-minute delay
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia
FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome
Vanda is developing important new medicines to improve the lives of patients. We use new technologies, including genetics and genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. We are working to advance the science of developing new medicines and to use novel approaches to deliver these new medicines to patients.
Our CEO, Mihales Polymeropoulos, MD, founded Vanda in 2003. Previously, he founded and ran the Novartis global Pharmacogenetics department, one of the industry leaders. Prior to that he worked for many years at the National Institute of Mental Health and the National Human Genome Research Institute, where he did pioneering work in gene mapping. He founded Vanda in partnership with Care Capital LLC, the prominent biopharmaceuticals-focused investment firm, and Bio*One Capital, an investment arm of the Singapore government with a focus on new biomedical enterprises.
Vanda has assembled an experienced team and a stable of clinical stage compounds to deliver on its vision.
Bank of America
Joel Beatty, M.D.
Chris Howerton, Ph.D.
Vanda Pharmaceuticals Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Vanda Pharmaceuticals Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vanda Pharmaceuticals Inc. or its management. Vanda Pharmaceuticals Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
For members of the press or investor community who wish to obtain more information about Vanda, please contact:
Chief Corporate Affairs and Communications Officer
Vanda Pharmaceuticals Inc.
To request information, please fill out and submit the form below.*Required fields